Sun Pharma bets on generic Gleevec


Sun Pharma is betting that its generic version of Novartis’ leukaemia drug Gleevec will quickly get one third of US sales. Sun is hoping to reach one third of the market within 6 months. Sun’s generic Gleevec is 30 percent cheaper than the original, which could cost up to $90,000 annually in the US.

Read the source article at Business Standard

About the Author

Related Posts

Leave a Reply